 |
| ||||||||||||||
 |
||||||||||||||
|
|
 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. commands a group of promising compounds in a rich pipeline. Currently OPDC has numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal and neuroscience systems, and to treat cancer and ophthalmic disorders. |
| * OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989 |